Lilly (NYSE:LLY) has submitted marketing applications for Omvoh for Crohn's disease worldwide, including the European Union and Japan. The product is approved for the treatment of ulcerative ...

Omvoh is approved in more than 40 countries for UC and Lilly has also submitted marketing applications for the drug in Crohn's in most major markets, including the EU and Japan. GlobalData has ...

Lilly said the new drug – which will be sold under the Omvoh brand – will be launched in the coming weeks. It has already been approved under the same trade name in Europe and Japan ...

Lilly has submitted marketing applications around the globe, including in Canada, Japan and China, with additional global regulatory submissions planned. Omvoh is also approved in 44 countries ...

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active Crohn’s disease patients. The VIVID-2 trial has been evaluating continuous ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Omvoh has possible interactions with certain vaccines. Examples include the chickenpox vaccine and the nasal spray flu vaccine (FluMist). Talk with your doctor to avoid potentially harmful effects ...